Verastem (VSTM) Net Income towards Common Stockholders (2011 - 2026)
Verastem (VSTM) recorded quarterly Net Income towards Common Stockholders of -$44.0 million in Q1 2026, down 151.53% quarter-over-quarter from $85.4 million in Q4 2025, and down 1.33% on a YoY basis from -$44.6 million in Q1 2025.
Verastem (VSTM) Net Income towards Common Stockholders (2011 - 2026) Analysis & Trends
Verastem's Net Income towards Common Stockholders history runs 16 years deep, the most recent figure standing at -$44.0 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 1.33% year-over-year to -$44.0 million; the TTM figure through Mar 2026 stood at -$41.5 million (up 68.34% YoY), while the FY2025 annual figure was -$209.5 million, down 60.33% from the prior year.
- Net Income towards Common Stockholders was -$44.0 million for Q1 2026 at Verastem, down from $85.4 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $85.4 million in Q4 2025 to a low of -$44.0 million in Q1 2026.
- Historically, Net Income towards Common Stockholders has averaged -$21.4 million across 5 years, with a median of -$22.0 million in 2022.
- Biggest YoY gain for Net Income towards Common Stockholders was 367.0% in 2025; the steepest drop was 133.52% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$16.8 million in 2022, then tumbled by 80.88% to -$30.4 million in 2023, then retreated by 5.19% to -$32.0 million in 2024, then jumped by 367.0% to $85.4 million in 2025, then plunged by 151.53% to -$44.0 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$44.0 million (Q1 2026), $85.4 million (Q4 2025), and -$39.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Verastem | 407.42 Mn | 225.74 Mn | 15.90 Mn | -43.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -43.98 Mn |
| Dec 31, 2025 | 85.35 Mn |
| Sep 30, 2025 | -39.85 Mn |
| Jun 30, 2025 | -43.04 Mn |
| Mar 31, 2025 | -43.41 Mn |
| Dec 31, 2024 | -31.97 Mn |
| Sep 30, 2024 | -37.35 Mn |
| Jun 30, 2024 | -18.43 Mn |
| Mar 31, 2024 | -27.82 Mn |
| Dec 31, 2023 | -30.39 Mn |
| Sep 30, 2023 | -20.19 Mn |
| Jun 30, 2023 | -20.29 Mn |
| Mar 31, 2023 | -19.14 Mn |
| Dec 31, 2022 | -16.80 Mn |
| Sep 30, 2022 | -18.11 Mn |
| Jun 30, 2022 | -21.96 Mn |
| Mar 31, 2022 | -16.99 Mn |
| Dec 31, 2021 | -16.48 Mn |
| Sep 30, 2021 | -22.79 Mn |
| Jun 30, 2021 | -16.90 Mn |